HC Wainwright set a $3.00 price objective on Eyegate Pharmaceuticals (NASDAQ:EYEG) in a research report report published on Sunday, March 11th. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.
Separately, ValuEngine raised Eyegate Pharmaceuticals from a strong sell rating to a sell rating in a report on Friday, February 2nd.
Eyegate Pharmaceuticals (NASDAQ EYEG) opened at $0.61 on Friday. Eyegate Pharmaceuticals has a twelve month low of $0.50 and a twelve month high of $2.58. The firm has a market capitalization of $10.52, a price-to-earnings ratio of -0.65 and a beta of 3.37.
Eyegate Pharmaceuticals Company Profile
Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.
Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.